In_IN Vitro_NP Whole-Blood_NP Analysis_NP of_IN Cellular_NP Immunity_NP in_IN Patients_NPS with_IN Active_JJ Coccidioidomycosis_NN by_IN Using_VBG the_DT Antigen_NN Preparation_NN T27K_NP Measurement_NP of_IN cellular_JJ immunity_NN in_IN human_JJ coccidioidomycosis_NN has_VBZ important_JJ diagnostic_JJ and_CC prognostic_JJ implications_NNS ._SENT The_DT coccidioidin_NN skin_NN test_NN has_VBZ been_VBN the_DT standard_NN for_IN the_DT measurement_NN of_IN this_DT ,_, but_CC it_PP is_VBZ not_RB available_JJ in_IN the_DT United_NP States_NPS ._SENT We_PP examined_VBD the_DT utility_NN of_IN measuring_VBG surface_NN expression_NN of_IN CD69_NP on_IN T_NN lymphocytes_NNS in_IN whole_JJ blood_NN incubated_VBN with_IN the_DT coccidioidal_JJ antigen_NN preparation_NN T27K_NP as_IN an_DT alternative_NN to_TO the_DT skin_NN test_NN ._SENT Seventy_CD donors_NNS with_IN active_JJ coccidioidomycosis_NN were_VBD studied_VBN ._SENT The_DT mean_JJ fluorescent_JJ intensity_NN (_( MFI_NP )_) of_IN CD69_NP expression_NN on_IN CD3_NP lymphocytes_NNS in_IN response_NN to_TO T27K_NP was_VBD 28.61_CD +-_NN 1.77_CD ,_, significantly_RB greater_JJR than_IN the_DT control_NN response_NN of_IN 11.45_CD +-_NN 0.78_CD (_( P_NN <_SYM 0.001_CD )_) ._SENT The_DT MFI_NP CD69_NP response_NN to_TO T27K_NP above_IN that_DT for_IN the_DT control_NN (_( MFI_NP CD69_NP above_IN control_NN )_) was_VBD 6.35_CD +-_NN 2.18_CD for_IN seven_CD subjects_NNS with_IN disseminated_VBN coccidioidomycosis_NN who_WP were_VBD studied_VBN within_IN 5_CD months_NNS of_IN diagnosis_NN ._SENT This_DT was_VBD significantly_RB below_IN the_DT value_NN of_IN 20.17_CD +-_NN 3.17_CD for_IN 18_CD subjects_NNS with_IN pulmonary_JJ coccidioidomycosis_NN studied_VBN within_IN 5_CD months_NNS of_IN diagnosis_NN and_CC the_DT value_NN of_IN 19.58_CD +-_NN 2.91_CD for_IN 27_CD subjects_NNS with_IN disseminated_VBN coccidioidomycosis_NN studied_VBN after_IN 5_CD months_NNS of_IN diagnosis_NN (_( for_IN both_DT ,_, P_NN <_SYM 0.05_CD )_) ._SENT There_EX was_VBD an_DT inverse_JJ correlation_NN between_IN coccidioidal_JJ clinical_JJ score_NN and_CC MFI_NP CD69_NP above_IN control_NN for_IN all_DT 34_CD subjects_NNS with_IN disseminated_VBN coccidioidomycosis_NN (_( r_LS =_SYM 0.362_CD ;_: P_NN =_SYM 0.036_CD )_) but_CC not_RB for_IN the_DT 36_CD subjects_NNS with_IN pulmonary_JJ disease_NN (_( r_LS <_SYM 0.001_CD ;_: P_NN =_SYM 0.993_CD )_) ._SENT Among_IN 30_CD subjects_NNS for_IN whom_WP data_NNS were_VBD available_JJ ,_, there_EX was_VBD a_DT highly_RB significant_JJ association_NN between_IN the_DT MFI_NP CD69_NP above_IN control_NN and_CC the_DT supernatant_JJ concentrations_NNS of_IN gamma_NN interferon_NN ,_, interleukin-2_JJ (_( IL-2_NP )_) ,_, and_CC tumor_NN necrosis_NN factor_NN alpha_NN (_( for_IN all_DT ,_, P_NN <_SYM 0.001_CD )_) ,_, but_CC not_RB for_IN IL-4_NN ,_, IL-5_NP ,_, or_CC IL-10_NP ._SENT These_DT data_NNS indicate_VBP that_IN in_IN vitro_NN assessment_NN of_IN CD69_NP expression_NN on_IN T_NN lymphocytes_NNS by_IN using_VBG T27K_NP may_MD be_VB a_DT useful_JJ measure_NN of_IN cellular_JJ immune_JJ response_NN among_IN subjects_NNS with_IN active_JJ coccidioidomycosis_NN ._SENT The_DT association_NN between_IN expression_NN of_IN delayed-type_NN hypersensitivity_NN and_CC the_DT severity_NN of_IN illness_NN in_IN human_JJ coccidioidomycosis_NN has_VBZ been_VBN recognized_VBN for_IN more_JJR than_IN 50_CD years_NNS ._SENT Specifically_RB ,_, expression_NN of_IN delayed-type_NN hypersensitivity_NN is_VBZ predominantly_RB absent_JJ often_RB among_IN individuals_NNS who_WP have_VBP severe_JJ ,_, extrathoracic_JJ dissemination_NN ._SENT On_IN the_DT other_JJ hand_NN ,_, delayed-type_NN hypersensitivity_NN is_VBZ usually_RB present_JJ among_IN those_DT with_IN mild_JJ ,_, self-limited_JJ illness_NN ._SENT Moreover_RB ,_, the_DT failure_NN to_TO express_VB coccidioidal_JJ delayed-type_NN hypersensitivity_NN appears_VBZ to_TO predict_VB subsequent_JJ relapse_NN after_IN therapy_NN for_IN patients_NNS with_IN active_JJ coccidioidomycosis_NN is_VBZ halted_VBN ._SENT Immunologically_RB ,_, delayed-type_NN hypersensitivity_NN is_VBZ an_DT expression_NN of_IN cell-mediated_JJ immunity_NN ._SENT While_IN measurement_NN of_IN induration_NN at_IN the_DT site_NN of_IN intradermal_JJ injection_NN of_IN antigen_NN has_VBZ been_VBN the_DT traditional_JJ way_NN to_TO measure_VB cell-mediated_JJ immunity_NN ,_, in_IN vitro_NN laboratory_NN techniques_NNS also_RB are_VBP capable_JJ of_IN assessing_VBG cellular_JJ immunity_NN in_IN coccidioidomycosis_NN ._SENT In_IN vitro_NN methods_NNS are_VBP advantageous_JJ in_IN that_WDT they_PP do_VBP not_RB require_VB exposure_NN of_IN the_DT subject_NN to_TO foreign_JJ antigen_NN or_CC its_PP$ preservative_NN and_CC results_NNS are_VBP not_RB dependent_JJ on_IN injection_NN technique_NN ,_, time_NN of_IN reading_NN ,_, and_CC measurement_NN of_IN induration_NN size_NN ._SENT In_IN coccidioidomycosis_NN ,_, the_DT use_NN of_IN in_IN vitro_NN methods_NNS to_TO measure_VB cell-mediated_JJ immunity_NN has_VBZ taken_VBN on_IN further_JJR importance_NN because_IN no_DT skin-test_NN reagent_NN has_VBZ been_VBN available_JJ in_IN the_DT United_NP States_NPS for_IN the_DT past_JJ several_JJ years_NNS ._SENT In_IN the_DT present_JJ study_NN ,_, we_PP assessed_VBD in_IN vitro_NN expression_NN of_IN cellular_JJ immunity_NN in_IN coccidioidomycosis_NN by_IN measuring_VBG the_DT T-lymphocyte_NP surface_NN expression_NN of_IN CD69_NP ,_, a_DT glycoprotein_NN that_WDT is_VBZ expressed_VBN by_IN activated_VBN lymphocytes_NNS and_CC NK_JJ cells_NNS ,_, after_IN incubation_NN of_IN whole_JJ blood_NN with_IN the_DT antigen_NN preparation_NN T27K_NP ._SENT In_IN the_DT present_JJ work_NN ,_, we_PP compared_VBD CD69_NP expression_NN with_IN simultaneous_JJ cytokine_NN production_NN among_IN donors_NNS with_IN various_JJ forms_NNS of_IN active_JJ coccidioidomycosis_NN ._SENT We_PP have_VBP previously_RB shown_VBN that_IN in_IN vitro_NN assessment_NN of_IN cellular_JJ immunity_NN by_IN flow_NN cytometry_NN with_IN the_DT antigen_NN T27K_NN distinguishes_VBZ immune_JJ and_CC nonimmune_JJ healthy_JJ donors_NNS on_IN the_DT basis_NN of_IN coccidioidal_JJ skin_NN testing_NN when_WRB the_DT antigen_NN was_VBD still_RB available_JJ ._SENT Human_JJ subjects_NNS ._SENT |_SYM Seventy_NN patients_NNS with_IN active_JJ coccidioidomycosis_NN were_VBD sequentially_RB recruited_VBN and_CC tested_VBN as_IN they_PP entered_VBD the_DT Valley_NP Fever_NP Clinic_NP of_IN the_DT Southern_NP Arizona_NP Veterans_NPS Affairs_NPS Health_NP Care_NP System_NP ._SENT In_IN this_DT medical_JJ center_NN ,_, all_PDT those_DT with_IN a_DT diagnosis_NN of_IN coccidioidomycosis_NN are_VBP referred_VBN to_TO the_DT Valley_NP Fever_NP Clinic_NP ._SENT Donors_NNS known_VBN to_TO be_VB infected_VBN with_IN human_JJ immunodeficiency_NN virus_NN or_CC known_VBN to_TO have_VB undergone_VBN allogeneic_JJ transplantation_NN were_VBD excluded_VBN from_IN the_DT study_NN ._SENT A_DT variety_NN of_IN clinical_JJ data_NNS were_VBD collected_VBN at_IN the_DT time_NN of_IN study_NN ,_, and_CC a_DT clinical_JJ score_NN of_IN severity_NN of_IN coccidioidomycosis_NN was_VBD determined_VBN ._SENT This_DT score_NN is_VBZ based_VBN on_IN clinical_JJ symptoms_NNS ,_, the_DT severity_NN and_CC number_NN of_IN clinical_JJ sites_NNS of_IN disease_NN ,_, and_CC the_DT immune_JJ diffusion_NN complement-fixing_VBG coccidioidal_JJ antibody_NN titer_NN ._SENT In_IN this_DT system_NN ,_, a_DT higher_JJR score_NN is_VBZ associated_VBN with_IN more_JJR severe_JJ coccidioidal_JJ illness_NN ._SENT The_DT study_NN was_VBD approved_VBN by_IN the_DT Human_NP Subjects_NPS Committee_NP of_IN the_DT University_NP of_IN Arizona_NP ._SENT In_IN addition_NN to_TO these_DT patients_NNS ,_, 20_CD healthy_JJ donors_NNS with_IN known_VBN reactivity_NN to_TO coccidioidin_NN and_CC without_IN active_JJ coccidioidomycosis_NN and_CC 11_CD healthy_JJ donors_NNS without_IN known_VBN coccidioidal_JJ immunity_NN were_VBD also_RB studied_VBN ._SENT Whole-blood_NN preparation_NN and_CC incubation_NN ._SENT |_SYM Approximately_RB 5_CD ml_NN of_IN blood_NN was_VBD drawn_VBN by_IN venipuncture_NN from_IN each_DT donor_NN and_CC placed_VBN into_IN tubes_NNS containing_VBG lithium_NN heparin_NN ._SENT Aliquots_NNS of_IN 0.5_CD ml_NN were_VBD added_VBN to_TO 15-ml_JJ polypropylene_NN conical_JJ centrifuge_NN tubes_NNS (_( Corning_NP ,_, Corning_NP ,_, N.Y._NP )_) to_TO which_WDT 10_CD or_CC 20_CD mug_NN of_IN T27K_NP per_IN ml_NN was_VBD added_VBN ._SENT Previous_JJ studies_NNS did_VBD not_RB reveal_VB differences_NNS between_IN the_DT two_CD concentrations_NNS ._SENT Nothing_NN was_VBD added_VBN to_TO control_VB tubes_NNS ._SENT T27K_NP was_VBD prepared_VBN as_IN a_DT solution_NN as_RB described_VBD previously_RB ._SENT Samples_NNS were_VBD incubated_VBN for_IN 18_CD to_TO 24_CD h_NN at_IN 37C_JJ in_IN 95_CD %_NN air-5_NN %_NN CO2_NP ,_, with_IN the_DT caps_NNS of_IN the_DT tubes_NNS kept_VBD loose_RB and_CC without_IN rocking_VBG ._SENT At_IN the_DT end_NN of_IN this_DT time_NN ,_, 50_CD mul_NN of_IN 20_CD mM_NP EDTA_NP (_( GIBCO_NP ,_, Grand_NP Island_NP ,_, N.Y._NP )_) was_VBD added_VBN to_TO each_DT sample_NN for_IN 15_CD min_NN at_IN room_NN temperature_NN ._SENT Subsequently_RB ,_, 5.0_CD ml_NN of_IN FACSlyse_NP (_( Becton_NP Dickinson_NP Immuno-cytometry_NP Systems_NPS ,_, [_SYM BDIS_NP ]_SYM ,_, San_NP Jose_NP ,_, Calif._NP )_) was_VBD added_VBN to_TO each_DT tube_NN to_TO lyse_VB red_JJ blood_NN cells_NNS ._SENT The_DT tubes_NNS were_VBD incubated_VBN for_IN 10_CD min_NN at_IN room_NN temperature_NN ,_, and_CC then_RB the_DT contents_NNS were_VBD mixed_VBN ._SENT Following_VBG this_DT ,_, the_DT samples_NNS were_VBD centrifuged_VBN ,_, resuspended_VBN in_IN 5.0_CD ml_NN of_IN wash_NN buffer_NN (_( phosphate-buffered_JJ saline_NN with_IN 1_CD %_NN bovine_JJ serum_NN albumin_NN and_CC 0.1_CD %_NN NaN3_NP )_) ,_, and_CC recentrifuged_JJ ;_: and_CC the_DT pellet_NN was_VBD resuspended_VBN in_IN 1.0_CD ml_NN of_IN wash_NN buffer_NN ._SENT To_TO 200_CD mul_NN of_IN each_DT sample_NN was_VBD added_VBN 20_CD mul_NN of_IN phycoerythrin_NN (PE)-labeled_JJ anti-CD69_NN and_CC 20_CD mul_NN of_IN peridinin_NN chlorophyll_NN protein-labeled_JJ anti-CD3_NP (_( BDIS_NP )_) ,_, and_CC the_DT mixture_NN was_VBD incubated_VBN for_IN 30_CD min_NN at_IN room_NN temperature_NN in_IN the_DT dark_NN ._SENT Then_RB ,_, 2.0_CD ml_NN of_IN wash_NN buffer_NN was_VBD added_VBN to_TO each_DT sample_NN ,_, the_DT samples_NNS were_VBD centrifuged_VBN again_RB ,_, and_CC the_DT pellet_NN was_VBD resuspended_VBN in_IN 500_CD mul_NN of_IN phosphate-buffered_JJ saline_NN ._SENT After_IN this_DT step_NN ,_, the_DT samples_NNS were_VBD immediately_RB used_VBN for_IN flow_NN cytometry_NN ._SENT Flow_NN cytometry_NN ._SENT |_SYM Cells_NP were_VBD analyzed_VBN with_IN a_DT single_JJ argon-ion_NN laser_NN flow_NN cytometer_NN (_( 488_CD nm_NN ;_: FACScan_NP ;_: Becton_NP Dickinson_NP ,_, Mountain_NP View_NP ,_, Calif._NP )_) with_IN Cell_NP Quest_NP software_NN (_( Becton_NP Dickinson_NP )_) ._SENT Prior_RB to_TO each_DT assay_NN ,_, general_JJ calibration_NN and_CC compensation_NN were_VBD established_VBN by_IN using_VBG two-color_JJ CaliBRITE_NP beads_NNS (_( Becton_NP Dickinson_NP )_) ,_, prepared_VBN according_VBG to_TO the_DT directions_NNS of_IN the_DT manufacturer_NN ,_, with_IN the_DT results_NNS analyzed_VBN by_IN using_VBG FACSComp_NP software_NN (_( version_NN 4.1_CD ;_: Becton_NP Dickinson_NP )_) ._SENT For_IN every_DT use_NN ,_, a_DT printout_NN was_VBD generated_VBN detailing_VBG the_DT photomultiplier_NN tube_NN (_( PMT_NP )_) voltages_NNS ,_, laser_NN current_JJ ,_, and_CC power_NN ._SENT Over_IN the_DT 6-month_JJ period_NN encompassing_VBG this_DT study_NN ,_, the_DT FLI_NP PMT_NP voltage_NN varied_VBN by_IN 14_CD V_CD (_( 620_CD to_TO 634_CD V_CD )_) ,_, the_DT FL2_NP PMT_NP voltage_NN varied_VBN by_IN 26_CD V_CD (_( 664_CD to_TO 680_CD V_CD )_) ,_, and_CC the_DT FL3_NP PMT_NP voltage_NN varied_VBN by_IN 32_CD V_CD (_( 704_CD to_TO 736_CD V_CD )_) ._SENT In_IN addition_NN ,_, the_DT laser_NN current_NN varied_VBN between_IN 5.18_CD and_CC 5.22_CD A_DT ,_, and_CC the_DT laser_NN power_NN varied_VBN between_IN 15.00_CD and_CC 15.05_CD mW_NNS ._SENT In_IN addition_NN to_TO these_DT general_JJ steps_NNS ,_, a_DT sample_NN was_VBD prepared_VBN from_IN T27K-stimulated_JJ cells_NNS for_IN each_DT experiment_NN containing_VBG fluorescein_NN isothiocyanate-labeled_JJ immunoglobulin_NN G2a_NP ,_, PE-labeled_JJ immunoglobulin_NN G1_NP ,_, and_CC PerCP-labeled_JJ anti-CD3_NN ._SENT From_IN this_DT ,_, a_DT CD3+-lymphocyte_NP gate_NN was_VBD established_VBN and_CC the_DT PMT_NP voltage_NN for_IN each_DT channel_NN was_VBD set_VBN ._SENT Compensation_NN was_VBD then_RB optimized_VBN by_IN analyzing_VBG samples_NNS containing_VBG fluorescein_NN isothiocyanate-_NN ,_, PE-_NP ,_, and_CC PerCP-labeled_JJ anti-CD8_NN within_IN the_DT CD3+-lymphocyte_NP gate_NN ._SENT Compensation_NN was_VBD considered_VBN optimized_VBN when_WRB the_DT positive_JJ populations_NNS were_VBD aligned_VBN over_IN the_DT negative_JJ populations_NNS ._SENT The_DT surface_NN expression_NN of_IN CD69_NP was_VBD then_RB assessed_VBN among_IN CD3_NP lymphocytes_NNS after_IN counting_VBG of_IN 10,000_CD of_IN these_DT cells_NNS for_IN each_DT sample_NN and_CC was_VBD recorded_VBN as_IN the_DT mean_JJ fluorescent_JJ intensity_NN (_( MFI_NP )_) ._SENT Cytokine_NP bead_NN assay_NN ._SENT |_SYM The_DT plasma_NN supernatant_JJ was_VBD drawn_VBN off_RP some_DT of_IN the_DT samples_NNS prior_RB to_TO preparation_NN for_IN flow_NN cytometry_NN and_CC was_VBD frozen_VBN at_IN -70C_NN ._SENT Subsequently_RB ,_, these_DT samples_NNS were_VBD thawed_VBN and_CC the_DT concentrations_NNS of_IN the_DT cytokines_NNS gamma_NN interferon_NN (_( IFN-gamma_NP )_) ,_, interleukin-2_NP (_( IL-2_NP )_) ,_, tumor_NN necrosis_NN factor_NN alpha_NN (_( TNF-alpha_NP )_) ,_, IL-4_NN ,_, IL-5_NP ,_, and_CC IL-10_NP were_VBD measured_VBN by_IN a_DT flow_NN cytometric_JJ bead_NN assay_NN (_( BDIS_NP )_) ._SENT Samples_NNS with_IN levels_NNS >5,000_JJ pg/ml_NN ,_, the_DT upper_JJ limit_NN of_IN the_DT assay_NN ,_, were_VBD not_RB rerun_VBN at_IN dilution_NN but_CC were_VBD instead_RB listed_VBN as_IN 5,000_CD pg/ml_NN ._SENT Statistics_NNS ._SENT |_SYM Statistical_NP analysis_NN of_IN continuous_JJ variables_NNS between_IN two_CD groups_NNS was_VBD performed_VBN by_IN the_DT Student_NP t_NN test_NN ,_, and_CC the_DT paired_VBN t_NN test_NN was_VBD used_VBN for_IN comparison_NN of_IN data_NNS within_IN subjects_NNS ._SENT Linear_NP regression_NN was_VBD used_VBN to_TO determine_VB the_DT association_NN of_IN continuous_JJ variables_NNS ._SENT A_DT contingency_NN table_NN was_VBD used_VBN to_TO assess_VB differences_NNS in_IN frequencies_NNS between_IN groups_NNS by_IN the_DT Fisher_NP exact_JJ test_NN being_VBG used_VBN for_IN two-by-two_NN tables_NNS ._SENT In_IN all_DT cases_NNS ,_, a_DT P_NN value_NN of_IN <0.050_NN was_VBD considered_VBN statistically_RB significant_JJ ._SENT Description_NN of_IN patients_NNS ._SENT |_SYM The_DT 70_CD patients_NNS consisted_VBN of_IN 34_CD individuals_NNS with_IN disseminated_VBN coccidioidomycosis_NN and_CC 36_CD patients_NNS with_IN pulmonary_JJ disease_NN ._SENT Reflecting_VBG the_DT population_NN of_IN veterans_NNS from_IN which_WDT the_DT study_NN population_NN was_VBD derived_VBN ,_, 67_CD of_IN the_DT subjects_NNS in_IN the_DT study_NN were_VBD male_JJ ,_, with_IN a_DT median_JJ age_NN of_IN 66.9_CD years_NNS (_( age_NN range_NN ,_, 26.8_CD to_TO 85.4_CD years_NNS )_) ._SENT In_IN addition_NN ,_, 21_CD were_VBD African_NP American_NP ,_, 67_CD were_VBD non-Hispanic_NP ,_, and_CC 5_CD were_VBD active_JJ cigarette_NN smokers_NNS ._SENT The_DT median_JJ time_NN since_IN the_DT diagnosis_NN of_IN coccidioidomycosis_NN upon_IN entry_NN into_IN the_DT study_NN was_VBD 8.9_CD months_NNS (_( range_NN ,_, 0.2_CD to_TO 289.4_CD months_NNS )_) ._SENT Forty-seven_NP patients_NNS were_VBD receiving_VBG some_DT type_NN of_IN antifungal_JJ therapy_NN at_IN the_DT time_NN of_IN the_DT study_NN ,_, while_IN 23_CD were_VBD not_RB ._SENT Thirty-four_NP of_IN the_DT patients_NNS had_VBD underlying_VBG diseases_NNS ._SENT Of_IN these_DT ,_, diabetes_NN was_VBD the_DT most_RBS common_JJ and_CC occurred_VBN in_IN 16_CD patients_NNS ._SENT Expression_NN of_IN CD69_NP in_IN response_NN to_TO T27K_NP ._SENT |_SYM Among_IN all_DT 70_CD patients_NNS ,_, the_DT mean_JJ +-_NN standard_JJ error_NN of_IN the_DT mean_JJ MFI_NP CD69_NP in_IN response_NN to_TO incubation_NN with_IN T27K_NP was_VBD 28.61_CD +-_NN 1.77_CD ,_, significantly_RB greater_JJR than_IN the_DT response_NN of_IN the_DT control_NN ,_, whose_WP$ samples_NNS were_VBD not_RB incubated_VBN with_IN T27K_NP ,_, of_IN 11.45_CD +-_NN 0.78_CD (_( P_NN <_SYM 0.001_CD )_) ._SENT In_IN order_NN to_TO account_VB for_IN the_DT low_JJ but_CC persistent_JJ expression_NN of_IN CD69_NP by_IN CD3_NP lymphocytes_NNS without_IN antigen_NN stimulation_NN ,_, subsequent_JJ data_NNS are_VBP expressed_VBN as_IN the_DT difference_NN ,_, for_IN each_DT donor_NN ,_, in_IN MFI_NP CD69_NP between_IN the_DT sample_NN incubated_VBN with_IN T27K_NP and_CC the_DT control_NN sample_NN not_RB incubated_VBN with_IN T27K_NP (_( MFI_NP CD69_NP above_IN control_NN )_) ._SENT Hence_RB ,_, the_DT results_NNS for_IN each_DT donor_NN were_VBD normalized_VBN by_IN subtracting_VBG the_DT results_NNS for_IN the_DT sample_NN containing_VBG T27K_NP from_IN the_DT results_NNS for_IN the_DT control_NN sample_NN that_WDT did_VBD not_RB contain_VB T27K_NP ._SENT The_DT mean_JJ +-_NN standard_JJ error_NN of_IN the_DT mean_JJ MFI_NP CD69_NP above_IN control_NN in_IN response_NN to_TO T27K_NP for_IN all_DT 70_CD patients_NNS was_VBD 17.16_CD +-_NN 1.66_CD and_CC ranged_VBD from_IN -1.45_CD to_TO 53.7_CD ._SENT The_DT MFI_NP CD69_NP above_IN control_NN for_IN the_DT 34_CD patients_NNS with_IN disseminated_VBN coccidioidomycosis_NN was_VBD 16.86_CD +-_NN 2.52_CD and_CC was_VBD not_RB significantly_RB different_JJ from_IN value_NN for_IN the_DT 36_CD patients_NNS with_IN pulmonary_JJ disease_NN ,_, 17.44_CD +-_NN 2.22_CD (_( P_NN =_SYM 0.861_CD )_) ._SENT The_DT results_NNS for_IN the_DT patients_NNS with_IN active_JJ coccidioidomycosis_NN were_VBD not_RB significantly_RB different_JJ from_IN the_DT value_NN of_IN 15.21_CD +-_NN 1.58_CD obtained_VBN for_IN the_DT 20_CD healthy_JJ immune_JJ donors_NNS with_IN known_VBN coccidioidal_JJ immunity_NN (_( P_NN =_SYM 0.549_CD )_) ._SENT On_IN the_DT other_JJ hand_NN ,_, the_DT MFI_NP CD69_NP above_IN control_NN for_IN 11_CD healthy_JJ nonimmune_NN donors_NNS was_VBD only_RB 1.58_CD +-_NN 0.69_CD ,_, significantly_RB less_JJR than_IN the_DT values_NNS for_IN the_DT patients_NNS with_IN active_JJ coccidioidomycosis_NN and_CC the_DT healthy_JJ ,_, immune_JJ donors_NNS (_( for_IN all_DT ,_, P_NN <_0.001). 0.050_CD )_) (_( data_NNS not_RB shown_VBN )_) ._SENT Because_IN antifungal_JJ therapy_NN may_MD have_VB changed_VBN the_DT initial_JJ coccidioidal_JJ cellular_JJ immune_JJ response_NN over_IN time_NN ,_, particularly_RB among_IN those_DT with_IN disseminated_VBN disease_NN ,_, data_NNS were_VBD next_RB analyzed_VBN by_IN comparing_VBG subjects_NNS who_WP were_VBD studied_VBN within_IN 5_CD months_NNS of_IN diagnosis_NN to_TO those_DT who_WP were_VBD studied_VBN after_IN 5_CD months_NNS of_IN diagnosis_NN ._SENT These_DT data_NNS are_VBP displayed_VBN in_IN Fig._NN ._SENT Among_IN the_DT seven_CD subjects_NNS with_IN disseminated_VBN coccidioidomycosis_NN studied_VBN within_IN 5_CD months_NNS of_IN diagnosis_NN ,_, the_DT MFI_NP CD69_NP above_IN control_NN was_VBD 6.35_CD +-_NN 2.18_CD ,_, significantly_RB less_JJR than_IN the_DT value_NN of_IN 20.17_CD +-_NN 3.17_CD for_IN the_DT 18_CD subjects_NNS with_IN pulmonary_JJ coccidioidomycosis_NN studied_VBN within_IN 5_CD months_NNS of_IN diagnosis_NN (_( P_NN =_SYM 0.016_CD )_) and_CC the_DT value_NN of_IN 19.58_CD +-_NN 2.91_CD for_IN the_DT 27_CD patients_NNS with_IN disseminated_VBN coccidioidomycosis_NN studied_VBD more_JJR than_IN 5_CD months_NNS after_IN diagnosis_NN (_( P_NN =_SYM 0.031_CD )_) ._SENT This_DT difference_NN was_VBD not_RB due_JJ to_TO a_DT difference_NN in_IN background_NN expression_NN of_IN CD69_NP ._SENT The_DT expression_NN of_IN CD69_NP in_IN control_NN ,_, unstimulated_JJ samples_NNS from_IN those_DT with_IN a_DT diagnosis_NN of_IN pulmonary_JJ coccidioidomycosis_NN of_IN less_JJR than_IN 5_CD months_NNS '_POS duration_NN was_VBD 8.45_CD +-_NN 1.38_CD ,_, not_RB different_JJ from_IN the_DT value_NN of_IN 10.83_CD +-_NN 3.30_CD for_IN those_DT with_IN disseminated_VBN disease_NN of_IN less_JJR than_IN 5_CD months_NNS '_POS duration_NN (_( P_NN =_SYM 0.434_CD )_) ._SENT Association_NP of_IN CD69_NP expression_NN in_IN response_NN to_TO T27K_NP and_CC clinical_JJ coccidioidomycosis_NN score_NN ._SENT |_SYM As_RB shown_VBN in_IN Fig._NN ,_, among_IN the_DT 34_CD subjects_NNS with_IN disseminated_VBN coccidioidomycosis_NN ,_, the_DT MFI_NP CD69_NP above_IN control_NN in_IN response_NN to_TO T27K_NP was_VBD found_VBN to_TO be_VB significantly_RB and_CC inversely_RB associated_VBN with_IN the_DT clinical_JJ coccidioidomycosis_NN score_NN (_( r_LS =_SYM 0.362_CD ;_: P_NN =_SYM 0.036_CD )_) ._SENT On_IN the_DT other_JJ hand_NN ,_, among_IN the_DT 36_CD donors_NNS with_IN pulmonary_JJ coccidioidomycosis_NN ,_, there_EX was_VBD no_DT correlation_NN between_IN MFI_NP CD69_NP above_IN control_NN in_IN response_NN to_TO T27K_NP and_CC the_DT clinical_JJ coccidioidomycosis_NN score_NN (_( r_LS <_SYM 0.001_CD ;_: P_NN =_SYM 0.993_CD )_) ._SENT Association_NP of_IN CD69_NP response_NN with_IN cytokine_NN production_NN ._SENT |_SYM For_IN 30_CD subjects_NNS ,_, the_DT plasma_NN supernatant_JJ was_VBD saved_VBN and_CC subsequently_RB tested_VBN to_TO determine_VB the_DT relationship_NN between_IN CD69_NP expression_NN and_CC cytokine_NN production_NN after_IN incubation_NN with_IN 10_CD mug_NN of_IN T27K_NP per_IN ml_NN ._SENT Fifteen_CD of_IN these_DT donors_NNS had_VBD disseminated_VBN coccidioidomycosis_NN and_CC 15_CD had_VBD pulmonary_JJ disease_NN ._SENT As_IN depicted_VBN in_IN Fig._NN ,_, there_EX was_VBD a_DT highly_RB significant_JJ and_CC positive_JJ association_NN between_IN MFI_NP CD69_NP above_IN control_NN and_CC the_DT concentrations_NNS of_IN IFN-gamma_NP ,_, IL-2_NP ,_, and_CC TNF-alpha_NP in_IN the_DT plasma_NN supernatant_JJ (_( for_IN all_DT three_CD ,_, P_NN <_SYM 0.001_CD )_) ._SENT The_DT levels_NNS of_IN IL-4_NN ,_, IL-5_NP ,_, and_CC IL-10_NP were_VBD low_JJ and_CC not_RB significantly_RB associated_VBN with_IN MFI_NP CD69_NP above_IN control_NN ._SENT The_DT relation_NN between_IN CD69_NP expression_NN and_CC cytokine_NN production_NN was_VBD not_RB different_JJ among_IN the_DT donors_NNS with_IN disseminated_VBN or_CC pulmonary_JJ coccidioidomycosis_NN (_( data_NNS not_RB shown_VBN )_) ._SENT FIG._NN 1_CD ._SENT |_SYM MFI_NP CD69_NP above_IN control_NN for_IN CD3_NP lymphocytes_NNS in_IN response_NN to_TO T27K_NP among_IN 34_CD donors_NNS with_IN disseminated_VBN coccidioidomycosis_NN (_( black_JJ boxes_NNS )_) and_CC 36_CD donors_NNS with_IN pulmonary_JJ coccidioidomycosis_NN (_( open_JJ boxes_NNS )_) ._SENT MFI_NP CD69_NP above_IN control_NN for_IN CD3_NP lymphocytes_NNS in_IN response_NN to_TO T27K_NP among_IN 34_CD donors_NNS with_IN disseminated_VBN coccidioidomycosis_NN (_( black_JJ boxes_NNS )_) and_CC 36_CD donors_NNS with_IN pulmonary_JJ coccidioidomycosis_NN (_( open_JJ boxes_NNS )_) ._SENT Patients_NNS studied_VBN within_IN 5_CD months_NNS of_IN diagnosis_NN were_VBD compared_VBN to_TO those_DT studied_VBD more_JJR than_IN 5_CD months_NNS after_IN diagnosis_NN ._SENT *_SYM ,_, P_NN <_SYM 0.05_CD when_WRB donors_NNS with_IN disseminated_VBN coccidioidomycosis_NN studied_VBN within_IN 5_CD months_NNS of_IN diagnosis_NN are_VBP compared_VBN to_TO donors_NNS with_IN pulmonary_JJ disease_NN studied_VBN within_IN 5_CD months_NNS of_IN diagnosis_NN and_CC donors_NNS with_IN disseminated_VBN disease_NN studied_VBN after_IN 5_CD months_NNS of_IN diagnosis_NN ._SENT Values_NNS in_IN parentheses_NNS indicate_VBP the_DT number_NN of_IN subjects_NNS in_IN each_DT group_NN ._SENT FIG._NN 2_CD ._SENT |_SYM Correlation_NN between_IN clinical_JJ coccidioidomycosis_NN score_NN and_CC MFI_NP CD69_NP above_IN control_NN in_IN response_NN to_TO T27K_NP among_IN 34_CD subjects_NNS with_IN disseminated_VBN coccidioidomycosis_NN and_CC 36_CD subjects_NNS with_IN pulmonary_JJ coccidioidomycosis_NN ._SENT Correlation_NN between_IN clinical_JJ coccidioidomycosis_NN score_NN and_CC MFI_NP CD69_NP above_IN control_NN in_IN response_NN to_TO T27K_NP among_IN 34_CD subjects_NNS with_IN disseminated_VBN coccidioidomycosis_NN and_CC 36_CD subjects_NNS with_IN pulmonary_JJ coccidioidomycosis_NN ._SENT FIG._NN 3_CD ._SENT |_SYM Comparison_NP of_IN MFI_NP CD69_NP above_IN control_NN for_IN CD3_NP lymphocytes_NNS after_IN incubation_NN with_IN 10_CD mug_NN of_IN T27K_NP per_IN ml_NN and_CC the_DT concentrations_NNS of_IN IFN-gamma_NP ,_, IL-2_NP ,_, TNF-alpha_NP ,_, IL-4_NN ,_, IL-5_NP ,_, and_CC IL-10_NP in_IN plasma_NN supernatants_NNS among_IN 30_CD subjects_NNS with_IN coccidioidomycosis_NN ._SENT Comparison_NN of_IN MFI_NP CD69_NP above_IN control_NN for_IN CD3_NP lymphocytes_NNS after_IN incubation_NN with_IN 10_CD mug_NN of_IN T27K_NP per_IN ml_NN and_CC the_DT concentrations_NNS of_IN IFN-gamma_NP ,_, IL-2_NP ,_, TNF-alpha_NP ,_, IL-4_NN ,_, IL-5_NP ,_, and_CC IL-10_NP in_IN plasma_NN supernatants_NNS among_IN 30_CD subjects_NNS with_IN coccidioidomycosis_NN ._SENT Measurement_NN of_IN delayed-type_NN hypersensitivity_NN by_IN skin_NN testing_NN has_VBZ been_VBN the_DT standard_JJ technique_NN by_IN which_WDT cell-mediated_JJ immunity_NN has_VBZ been_VBN determined_VBN among_IN individuals_NNS with_IN coccidioidomycosis_NN ._SENT This_DT test_NN is_VBZ not_RB available_JJ in_IN the_DT United_NP States_NPS ,_, and_CC alternatives_NNS are_VBP required_VBN to_TO assess_VB coccidioidal_JJ cellular_JJ immunity_NN ._SENT Assessment_NN of_IN cellular_JJ immunity_NN in_IN coccidioidomycosis_NN serves_VBZ several_JJ purposes_NNS ._SENT First_RB ,_, it_PP may_MD be_VB used_VBN to_TO establish_VB the_DT prevalence_NN of_IN coccidioidal_JJ infection_NN in_IN a_DT population_NN within_IN a_DT geographic_JJ region_NN ._SENT Second_RB ,_, it_PP may_MD be_VB used_VBN to_TO determine_VB new_JJ infection_NN ,_, if_IN prior_JJ assessment_NN of_IN immunity_NN has_VBZ been_VBN performed_VBN and_CC has_VBZ been_VBN found_VBN to_TO be_VB lacking_VBG ._SENT Finally_RB ,_, expression_NN of_IN cell-mediated_JJ immunity_NN appears_VBZ to_TO reflect_VB a_DT protective_JJ host_NN response_NN and_CC may_MD auger_NN an_DT improved_VBN clinical_JJ outcome_NN among_IN individuals_NNS with_IN symptomatic_JJ coccidioidomycosis_NN ._SENT In_IN the_DT present_JJ study_NN ,_, the_DT surface_NN expression_NN of_IN CD69_NP on_IN CD3_NP lymphocytes_NNS after_IN incubation_NN with_IN the_DT coccidioidal_JJ antigen_NN preparation_NN T27K_NP was_VBD used_VBN to_TO ascertain_VB the_DT cellular_JJ immune_JJ status_NN of_IN donors_NNS with_IN active_JJ coccidioidomycosis_NN ._SENT The_DT response_NN to_TO T27K_NP of_IN samples_NNS from_IN all_DT donors_NNS was_VBD significantly_RB above_JJ that_IN for_IN unstimulated_JJ control_NN samples_NNS and_CC above_IN the_DT values_NNS obtained_VBN for_IN a_DT group_NN of_IN healthy_JJ ,_, nonimmune_JJ donors_NNS ._SENT When_WRB the_DT MFI_NP CD69_NP above_IN control_NN in_IN response_NN to_TO T27K_NP was_VBD examined_VBN ,_, there_EX was_VBD no_DT overall_JJ difference_NN in_IN response_NN between_IN donors_NNS with_IN disseminated_VBN coccidioidomycosis_NN and_CC those_DT with_IN pulmonary_JJ disease_NN ,_, nor_CC were_VBD there_RB differences_NNS in_IN response_NN on_IN the_DT basis_NN of_IN underlying_VBG disease_NN ,_, age_NN ,_, or_CC race_NN ._SENT The_DT average_JJ age_NN of_IN the_DT patients_NNS with_IN active_JJ coccidioidomycosis_NN was_VBD nearly_RB 67_CD years_NNS ._SENT While_IN this_DT appears_VBZ old_JJ ,_, recent_JJ data_NNS indicate_VBP that_IN symptomatic_JJ coccidioidomycosis_NN is_VBZ far_RB more_RBR prevalent_JJ among_IN those_DT aged_VBN 60_CD years_NNS and_CC over_RB than_IN among_IN younger_JJR subjects_NNS ._SENT Because_IN all_DT patients_NNS with_IN active_JJ coccidioidomycosis_NN at_IN the_DT medical_JJ center_NN were_VBD referred_VBN to_TO the_DT coccidioidomycosis_NN clinic_NN and_CC were_VBD eligible_JJ for_IN study_NN ,_, the_DT older_JJR age_NN most_RBS likely_RB reflects_VBZ the_DT predisposition_NN for_IN symptomatic_JJ illness_NN among_IN an_DT older_JJR age_NN group_NN rather_RB than_IN any_DT other_JJ factor_NN ._SENT However_RB ,_, there_EX were_VBD significant_JJ differences_NNS on_IN the_DT basis_NN of_IN the_DT length_NN of_IN time_NN between_IN diagnosis_NN and_CC study_NN ._SENT When_WRB studied_VBN early_RB in_IN the_DT course_NN of_IN their_PP$ illness_NN ,_, those_DT with_IN disseminated_VBN disease_NN had_VBD a_DT decreased_VBN response_NN to_TO T27K_NP compared_VBN to_TO the_DT response_NN of_IN either_CC those_DT studied_VBD later_RBR or_CC those_DT with_IN pulmonary_JJ disease_NN ._SENT These_DT data_NNS suggest_VBP that_IN antifungal_JJ therapy_NN may_MD ameliorate_VB the_DT depression_NN in_IN cellular_JJ immune_JJ response_NN that_WDT occurs_VBZ in_IN disseminated_VBN coccidioidomycosis_NN that_WDT has_VBZ been_VBN observed_VBN previously_RB ._SENT Barbee_NP and_CC Hicks_NP have_VBP demonstrated_VBN such_PDT a_DT return_NN in_IN cellular_JJ immune_JJ response_NN with_IN therapy_NN in_IN a_DT small_JJ cohort_NN of_IN patients_NNS using_VBG an_DT in_IN vitro_NP lymphocyte_NN transformation_NN assay_NN ._SENT We_PP are_VBP prospectively_RB examining_VBG the_DT cellular_JJ immune_JJ response_NN over_IN time_NN in_IN patients_NNS with_IN various_JJ forms_NNS of_IN coccidioidomycosis_NN on_IN antifungal_JJ therapy_NN to_TO more_RBR fully_RB explore_VB this_DT question_NN ._SENT The_DT coccidioidal_JJ antigen_NN preparation_NN T27K_NN used_VBN in_IN these_DT experiments_NNS is_VBZ the_DT soluble_JJ ,_, aqueous_JJ supernatant_JJ obtained_VBN after_IN mechanically_RB disrupted_VBN thimerosal-preserved_JJ spherules_NNS are_VBP centrifuged_VBN at_IN 27,000_CD x_SYM g._FW Previous_JJ work_NN with_IN formalin_NN as_IN the_DT preservative_NN has_VBZ shown_VBN that_IN it_PP protects_VBZ mice_NNS from_IN experimental_JJ coccidioidal_JJ infection_NN when_WRB combined_VBN with_IN alum_NN ._SENT To_TO date_NN ,_, the_DT components_NNS of_IN T27K_NP have_VBP not_RB been_VBN fully_RB defined_VBN ,_, but_CC several_JJ coccidioidal_JJ antigens_NNS have_VBP been_VBN identified_VBN in_IN the_DT preparation_NN ,_, including_VBG chitinase_NN ,_, chitobiase_NP ,_, aspartyl_NN protease_NN ,_, Ag2/proline-rich_NP antigen_NN ,_, alkaline_JJ phosphatase_NN ,_, serine_NN protease_NN ,_, and_CC tube_NN precipitin_NN ._SENT Some_DT of_IN these_DT antigens_NNS have_VBP been_VBN identified_VBN in_IN both_DT coccidioidin_NN and_CC spherulin_NN ,_, but_CC neither_RB of_IN the_DT latter_JJ two_CD preparations_NNS has_VBZ ever_RB been_VBN fully_RB characterized_VBN ._SENT The_DT use_NN of_IN T27K_NP in_IN an_DT in_IN vitro_NN assay_NN is_VBZ in_IN contrast_NN to_TO earlier_JJR studies_NNS ,_, in_IN which_WDT either_DT coccidioidin_NN or_CC spherulin_NN was_VBD used_VBN as_IN the_DT skin-test_NN reagent_NN ._SENT While_IN it_PP would_MD be_VB of_IN great_JJ interest_NN to_TO compare_VB these_DT older_JJR antigen_NN preparations_NNS to_TO T27K_NP ,_, they_PP are_VBP ,_, unfortunately_RB ,_, no_DT longer_RBR available_JJ ._SENT Because_IN of_IN the_DT laboratory_NN and_CC bioterrorism_NN risk_NN ,_, preparation_NN of_IN either_DT requires_VBZ a_DT licensed_JJ biosafety_NN level_NN 3_CD facility_NN ._SENT Moreover_RB ,_, significant_JJ lot-to-lot_NN variability_NN occurs_VBZ with_IN these_DT preparations_NNS ,_, making_VBG any_DT comparisons_NNS difficult_JJ ._SENT In_IN previous_JJ work_NN ,_, we_PP have_VBP found_VBN that_IN the_DT in_IN vitro_NN response_NN to_TO T27K_NP among_IN healthy_JJ donors_NNS corresponds_VBZ closely_RB with_IN skin-test_NN positivity_NN to_TO spherulin_NN ._SENT The_DT clinical_JJ score_NN is_VBZ a_DT measure_NN of_IN coccidioidal_JJ severity_NN and_CC is_VBZ increased_VBN in_IN patients_NNS with_IN severe_JJ disease_NN and_CC declines_NNS as_IN disease_NN improves_VBZ with_IN antifungal_JJ therapy_NN ._SENT There_EX was_VBD a_DT significant_JJ inverse_JJ association_NN between_IN the_DT score_NN of_IN coccidioidal_JJ illness_NN among_IN donors_NNS with_IN disseminated_VBN coccidioidomycosis_NN and_CC the_DT expression_NN of_IN CD69_NP ._SENT However_RB ,_, no_DT such_JJ association_NN was_VBD seen_VBN among_IN those_DT with_IN active_JJ pulmonary_JJ disease_NN ._SENT This_DT observation_NN is_VBZ consistent_JJ with_IN observations_NNS first_RB made_VBN by_IN Smith_NP and_CC Beard_NP with_IN the_DT use_NN of_IN coccidioidin_NN skin_NN testing_NN and_CC with_IN the_DT findings_NNS of_IN other_JJ investigators_NNS who_WP used_VBD both_DT skin_NN testing_NN and_CC in_IN vitro_NN assays_NNS of_IN cell-mediated_JJ immunity_NN ._SENT CD69_JJ expression_NN on_IN CD3_NP lymphocytes_NNS in_IN response_NN to_TO T27K_NP among_IN donors_NNS with_IN coccidioidomycosis_NN was_VBD directly_RB and_CC positively_RB associated_VBN with_IN production_NN of_IN the_DT cytokines_NNS IFN-gamma_NP and_CC IL-2_NP but_CC not_RB with_IN the_DT production_NN of_IN the_DT T-helper_NN type_NN 2_CD cytokines_NNS IL-4_NN ,_, IL-5_NP ,_, and_CC IL-10_NP ._SENT This_DT suggests_VBZ that_IN CD69_NP expression_NN is_VBZ associated_VBN with_IN a_DT T-helper_NN type_NN 1_CD cellular_JJ immune_JJ response_NN in_IN patients_NNS with_IN coccidioidomycosis_NN ._SENT These_DT data_NNS and_CC our_PP$ previous_JJ work_NN demonstrating_VBG clear_JJ distinctions_NNS between_IN healthy_JJ immune_JJ and_CC nonimmune_JJ donors_NNS suggest_VBP that_IN T27K_NP is_VBZ a_DT biologically_RB useful_JJ antigen_NN in_IN determining_VBG the_DT cellular_JJ immune_JJ response_NN to_TO coccidioidomycosis_NN ._SENT The_DT close_JJ association_NN between_IN the_DT production_NN of_IN T-helper_NN type_NN 1_CD cytokines_NNS ,_, particularly_RB IFN-gamma_NP ,_, and_CC CD69_NP expression_NN in_IN response_NN to_TO T27K_NP suggests_VBZ that_IN assessment_NN of_IN these_DT cytokines_NNS alone_RB or_CC in_IN association_NN with_IN CD69_NP expression_NN might_MD be_VB useful_JJ in_IN measuring_VBG the_DT coccidioidal_JJ cellular_JJ immune_JJ response_NN ._SENT At_IN this_DT time_NN ,_, we_PP do_VBP not_RB have_VB enough_JJ data_NNS to_TO determine_VB whether_IN this_DT is_VBZ the_DT case_NN ._SENT Studies_NNS to_TO examine_VB this_DT are_VBP planned_VBN for_IN the_DT future_NN ._SENT Expression_NN of_IN CD69_NP on_IN lymphocytes_NNS has_VBZ been_VBN shown_VBN to_TO be_VB associated_VBN with_IN cellular_JJ immune_JJ function_NN in_IN patients_NNS with_IN a_DT variety_NN of_IN other_JJ conditions_NNS ._SENT In_IN addition_NN ,_, other_JJ rapid_JJ assays_NNS have_VBP been_VBN found_VBN to_TO be_VB useful_JJ in_IN determining_VBG the_DT cellular_JJ immune_JJ response_NN in_IN patients_NNS with_IN other_JJ granulomatous_JJ conditions_NNS ._SENT In_IN particular_JJ ,_, the_DT measurement_NN of_IN IFN-gamma_NP in_IN whole_JJ blood_NN incubated_VBN with_IN tuberculin_NN antigen_NN has_VBZ been_VBN found_VBN to_TO compare_VB favorably_RB with_IN purified_VBN protein_NN derivative_JJ skin_NN testing_NN in_IN patients_NNS with_IN a_DT variety_NN of_IN forms_NNS of_IN tuberculosis_NN ._SENT In_IN the_DT present_JJ study_NN ,_, expression_NN of_IN CD69_NP on_IN CD3_NP lymphocytes_NNS in_IN response_NN to_TO the_DT coccidioidal_JJ antigen_NN preparation_NN T27K_NP was_VBD a_DT rapid_JJ ,_, easily_RB performed_VBN assay_NN that_WDT required_VBD less_JJR blood_NN than_IN many_JJ standard_JJ clinical_JJ laboratory_NN tests_NNS and_CC provided_VBN useful_JJ information_NN regarding_VBG coccidioidomycosis-specific_JJ cellular_JJ immunity_NN ._SENT Therefore_RB ,_, even_RB if_IN the_DT reagents_NNS for_IN performing_VBG coccidioidal_JJ skin_NN testing_NN were_VBD still_RB available_JJ ,_, there_EX would_MD be_VB several_JJ advantages_NNS to_TO using_VBG an_DT in_IN vitro_NN system_NN ,_, such_JJ as_IN measurement_NN of_IN CD69_NP expression_NN ._SENT The_DT present_JJ study_NN ,_, while_IN demonstrating_VBG clinical_JJ associations_NNS with_IN the_DT in_IN vitro_NN assay_NN ,_, did_VBD not_RB clearly_RB show_VB a_DT direct_JJ relationship_NN between_IN the_DT assay_NN result_NN and_CC clinical_JJ disease_NN or_CC outcome_NN ._SENT It_PP is_VBZ imperative_JJ that_IN further_JJR studies_NNS examining_VBG the_DT utility_NN of_IN in_IN vitro_NN measurement_NN of_IN coccidioidal_JJ cellular_JJ immunity_NN be_VB performed_VBN to_TO further_RBR assess_VB this_DT possibility_NN ._SENT 